Bayer Sells Nebido To Grünenthal Amid Shift In Focus To Cell And Gene Pipeline
Will Sell For Up To €500m
The major will use funds from the sale of its male hypogonadism product to invest in future innovation, which is likely to focus on high-risk high-reward cell and gene drug candidates.
